CH EPL (R5)
1.0.0 - trial-use Switzerland flag

CH EPL (R5), published by Federal Office of Public Health FOPH. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/bag-epl/bag-epl-fhir/ and changes regularly. See the Directory of published versions

Example RegulatedAuthorization: Reimbursement SL 21529

CH - EPL Reimbursement SL

url

FOPHDossierNumber

value: FOPH Dossier Number/21529

url

status

value: Reimbursed

url

statusDate

value: 2023-12-01

url

expiryDate

value: 2026-03-31

url

listingStatus

value: Listed

url

listingPeriod

value: 2023-12-01 --> 2025-12-31

url

firstListingDate

value: 2023-12-01

url

costShare

value: 10

url

gamme

value: Oral

value: CHF958.62 (CHF)

type: Ex-factory price

changeType: Price mutation after triennal review of pharmaceuticals

changeDate: 2023-12-01

url

CH - EPL Product Price

value: CHF1,113.95 (CHF)

type: Retail price

changeType: VAT-change

changeDate: 2024-01-01

url

CH - EPL Product Price

subject: PackagedProductDefinition: identifier = http://fhir.ch/ig/ch-epl/sid/pcid#Clinical Product Identifier#CH-7601001010604-6879301-001; containedItemQuantity = 30 Tablet; description = PAXLOVID Filmtabl 4x150mg/2x100mg

type: Reimbursement SL

Indications

-ExtensionReference
*ClinicalUseDefinition: type = indication

holder: Organization Pfizer AG

Generated Narrative: Organization #holder-Pfizer-AG

identifier: LOC Identifier/100015286, GLN Identifier/7601001010604

name: Pfizer AG